NICE says yes to Cimzia for RA patients
This article was originally published in Scrip
Executive Summary
NICE, England's health technology appraisal body, has given UCB's pegylated anti-TNF product Cimzia (certolizumab pegol) the green light for treating some NHS patients with rheumatoid arthritis (RA). However, the recommendation hinges on a patient access scheme.